Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 polymorphisms are associated with reduced warfarin dose.

Surgery - 1 Aug 2000

Freeman B D, Zehnbauer B A, McGrath S, Borecki I, Buchman T G

Abstract excerpt

BACKGROUND: Warfarin use is complicated by an erratic dose response. Interpatient variability associated with warfarin therapy may be partly attributable to polymorphisms of the cytochrome P450 (CYP) complex. The purpose of this study was to ascertain the frequency and influence of CYP polymorphisms on warfarin dosing in our patient population. METHODS: Patients receiving warfarin therapy were recruited from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Black or African American
Share to Black People

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme System

Share to Dose-Response Relationship, Drug

Share to Missouri

Share to Restriction Mapping

Share to Warfarin

Source

Identifiers

PMID: 10923005
DOI: 10.1067/msy.2000.107283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 polymorphisms are associated with reduced warfarin dose.PMID 10923005Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.Semantic proximity Read ↗

CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic DosingSemantic proximity Read ↗

Pharmacogenetics of warfarin.Semantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.Semantic proximity Read ↗

Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.Semantic proximity Read ↗

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Semantic proximity Read ↗

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.